THIOGAMMA IN NONALCOHOLIC FATTY LIVER DISEASE
- Autores: Golovanova EV1, Golovanova Y.V1
-
Afiliações:
- Edição: Nº 7 (2012)
- Páginas: 53-57
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279495
- ID: 279495
Citar
Texto integral
Resumo
The article is devoted to the topical problem of hepatology: current view on the pathogenesis, diagnosis and treatment of nonalcoholic fatty liver disease that develops in the metabolic syndrome. Clinical manifestations and diagnostic capabilities for detecting disease are discussed. Particular attention is paid to the treatment of nonalcoholic fatty liver disease with account of main pathogenetic mechanisms. The main important mechanisms of action of thioctic acid allowing to correct the disorders of carbohydrate and fat metabolism in the metabolic syndrome are presented.
Palavras-chave
Bibliografia
- Гастроэнтерология: национальное руководство / Под. ред. В.Т. Ивашкина, Т.Л. Лапиной. М., 2008.
- Руководство по гастроэнтерологии / Под редакцией Ф.И. Комарова, С.И. Рапопорта. М., 2010.
- Мехтиев С.Н., Гриневич В.Б., Кравчук Ю.А., Бращенкова А.В. Неалкогольная жировая болезнь печени: клиника, диагностика, лечение // Лечащий врач 2008. № 2. С. 29-37.
- Ivashkin V, Drapkina O. The prevalence of non-alcoholic fatty liver disease in Russian Federation. Gut 2009;58:1207.
- Звенигородская Л.А. Метаболический синдром: основы патогенеза, исследования в будущем // Экспериментальная и клиническая гастроэнтерология 2007. № 1.
- Lumeng L, Crabb DW. Alcoholic liver disease. Curr Opin Gastroenterol 2000;16:208-18.
- Moseley RH. Liver and biliary tract. Curr Opin Gastroenterol 2003;19:181-84.
- Niemela O, Parkkila S, Yla-Herttuala S, et al. Sequential acetaldehyde production, lipid peroxidation and fibrogenesis in micropig model of alcohol-induced liver disease. Hepatology 1995;22:1208-14.
- Яковенко Э.П., Григорьев П.Я., Агафонова Н.А. и др. Метаболические заболевания печени: проблемы терапии // Фарматека 2003. № 10 (73). С. 47-52.
- Konrad T, Vicini P, et al. Alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 1999;22(2):280-87.
- Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999;22(8):1296-301.
- Бабак О.Я., Колесникова Е.В. От механизмов повреждения - к фармакологической коррекции стеатоза и стеатогепатита // Здоров'я України 2010. № 9. С. 60-1.
- Schupke H, Hempel R, Peter G, et al. New metabolic pathways of alpha-lipoic acid. Drug metabolism and disposition: the biological fate of chemicals 2001;29(6):855-62.
- Morita Y, Ueno T, Sasaki N, et al. Nateglinide improves non-alcoholic steatohepatitis with type 2 diabetes. J Hepatol 2006;44(2):699.
- Mendez-Sanchez N, Arrese M, et al. Current concepts in patho-genesis of nonalcoholic fatty liver disease. Liver intern 2007;27(4):423-33.
- Cai D, Yuan M, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B. Nat Med 2005;11:183-90.
- Roberts EA. Pediatric nonalcoholic fatty liver disease(NAFLD): A "growing" problem? J Hepatol 2007;46(6):1133-42.
Arquivos suplementares
